Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Comment on "ALK is a therapeutic target for lethal sepsis".

Blasco RB, Patrucco E, Mota I, Tai WT, Chiarle R.

Sci Transl Med. 2018 Dec 12;10(471). pii: eaar4321. doi: 10.1126/scitranslmed.aar4321.

2.

Parp3 promotes long-range end joining in murine cells.

Layer JV, Cleary JP, Brown AJ, Stevenson KE, Morrow SN, Van Scoyk A, Blasco RB, Karaca E, Meng FL, Frock RL, Tivey T, Kim S, Fuchs H, Chiarle R, Alt FW, Roberts SA, Weinstock DM, Day TA.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10076-10081. doi: 10.1073/pnas.1801591115. Epub 2018 Sep 13.

3.

The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo.

Cheong TC, Blasco RB, Chiarle R.

Adv Exp Med Biol. 2018;1044:39-48. doi: 10.1007/978-981-13-0593-1_4.

PMID:
29956290
4.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

5.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.

Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

6.

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M.

Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.

PMID:
26855149
7.

Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.

Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R.

Cell Rep. 2014 Nov 20;9(4):1219-27. doi: 10.1016/j.celrep.2014.10.051. Epub 2014 Nov 13.

8.

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Blasco RB, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J, Baccarini M, Barbacid M.

Cancer Cell. 2011 May 17;19(5):652-63. doi: 10.1016/j.ccr.2011.04.002. Epub 2011 Apr 21.

Supplemental Content

Loading ...
Support Center